Ansell, CSL and ResMed: 3 stocks to buy now

Broker CLSA is seeing value in these 3 high quality healthcare stocks.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

According to a report on AFR.com, newly installed healthcare analysts at stock broker CLSA Zara Lyons and David Stanton have initiated coverage of the following three high quality healthcare stocks with 'buy' recommendations.

1. Ansell (ASX: ANN) manufacturers a range of gloves and condoms for the industrial, medical, specialty and retail sectors globally. The firm has a market capitalisation of $2.5 billion and has seen its shares rally nearly 23% in the past 12 months, which is slightly more than the 21.7% rise in the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO). With leverage to a growing global economy – particularly manufacturing – Ansell's long-term outlook for earnings growth looks solid.

2. CSL (ASX: CSL) is a vertically integrated biotech company. The firm conducts research, development, manufacturing, marketing and distribution of its products with a focus on treatments derived from human blood plasma. With global operations and a market capitalisation of $33.4 billion, the firm is well positioned to continue to grow and expand both its product offer and customer reach. CSL's shares have surged 48% in the past year however Lyons and Stanton obviously see further upside potential.

3. ResMed (ASX: RMD) is a leading provider of medical equipment for treating, diagnosing and managing breathing issues, with a particular focus on obstructive sleep apnea (OSA). ResMed has a market capitalisation of $7.3 billion but despite its market leading status it still only has a relatively small share of the OSA market, which means there is still enormous growth potential. The shares are up over 33% since October last year however the size of the undiagnosed OSA market means ResMed is still on an exciting growth trajectory.

Foolish takeaway

Warren Buffett learnt decades ago that buying great companies at conservative prices is a winning strategy. Ansell, CSL and ResMed all have the attributes of great companies including quality management, long runways of future growth and certain barriers to entry which help keep competitors away.

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »